烟酸控释片联合拉罗匹仑的安全性和耐受性。
Safety and tolerability of extended-release niacin with laropiprant.
机构信息
University of Manchester, School of Biomedicine, Cardiovascular Research Group, Core Technology Facility, 46, Grafton Street, Manchester, M13 9NT, UK.
出版信息
Expert Opin Drug Saf. 2012 Jan;11(1):151-9. doi: 10.1517/14740338.2011.638281. Epub 2011 Dec 1.
INTRODUCTION
Niacin is one of the oldest drugs used in the treatment of dyslipidemia. Previously its use has been limited because of excessive flushing. Now an agent laropiprant (LRP) has been developed, which blocks the flushing pathway. Therefore, it is time to collate available information to assess the safety and tolerability of combining niacin with LRP.
AREAS COVERED
The authors searched PubMed and MEDLINE for literature published between January 2006 and July 2011, for safety and tolerability reports of extended-release niacin (ERN) with LRP.
EXPERT OPINION
The addition of LRP to ERN, by reducing the side effect 'flushing', may enable lipidologists and physicians to use niacin more widely as part of lipid modification therapy, especially since the combination can be safely added to statins. However, it has to be accepted that the addition of LRP does not completely abolish flushing. The favorable safety profile supports the use of LRP to achieve higher therapeutic dosing of niacin.
简介
烟酸是用于治疗血脂异常的最古老药物之一。以前由于过度潮红，其使用受到限制。现在已经开发出一种叫做拉罗匹仑（LRP）的药物，它可以阻断潮红途径。因此，现在是时候整理可用信息，评估烟酸与 LRP 联合使用的安全性和耐受性了。
涵盖领域
作者在 PubMed 和 MEDLINE 上搜索了 2006 年 1 月至 2011 年 7 月之间发表的关于 LRP 与缓释烟酸（ERN）安全性和耐受性报告的文献。
专家意见
通过减少副作用“潮红”，将 LRP 添加到 ERN 中，可能使脂质学家和医生能够更广泛地将烟酸用作脂质修饰治疗的一部分，尤其是因为联合用药可以安全地添加到他汀类药物中。然而，必须承认，LRP 的添加并不能完全消除潮红。有利的安全性概况支持使用 LRP 来实现更高的烟酸治疗剂量。
Zotero 插件